Amedisys (AMED) Tops Q1 EPS by 11c; Offers FY22 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Amedisys Reports First Quarter 2022 Financial Results and Reaffirms 2022 Guidance
April 27, 2022 4:05 PM EDTBATON ROUGE, La., April 27, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2022.
Three-Month Periods Ended March 31, 2022 and 2021
Net service revenue increased $8.2Â million to $545.3Â million compared to $537.1Â million in 2021.Net income attributable to Amedisys, Inc. of $31.7Â million compared to $49.9Â million in 2021.Net income attributable to Amedisys, Inc. per diluted share of $0.97 compared to $1.50 in 2021.Adjusted Quarterly Results*
Adjusted EBITDA of $66.3Â million compared to $78.6Â million in 2021.Adjusted net income attributable to Amedisys, Inc. of $40.1Â million compared to $51.1Â million in... More